KROS Logo

Keros Therapeutics, Inc. (KROS) 

NASDAQ
Market Cap
$2.19B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
590 of 774
Rank in Industry
317 of 432

Largest Insider Buys in Sector

KROS Stock Price History Chart

KROS Stock Performance

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing …

Insider Activity of Keros Therapeutics, Inc.

Over the last 12 months, insiders at Keros Therapeutics, Inc. have bought $0 and sold $22M worth of Keros Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Keros Therapeutics, Inc. have bought $92.36M and sold $15.67M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 120,000 shares for transaction amount of $6M was made by Kariv Tomer () on 2020‑11‑17.

List of Insider Buy and Sell Transactions, Keros Therapeutics, Inc.

2024-08-13Saledirector
250,000
0.6566%
$44.01$11M0.00%
2024-08-13Saledirector
250,000
0.6566%
$44.01$11M0.00%
2023-11-04SaleChief Financial Officer
40,000
0.1912%
$45.29$1.81M+0.36%
2023-06-09SaleChief Financial Officer
20,000
0.073%
$45.42$908,367-6.61%
2023-06-08SaleChief Financial Officer
20,000
0.0688%
$47.79$955,872-16.16%
2022-07-15SaleChief Scientific Officer
46,034
0.1768%
$30.00$1.38M+44.95%
2022-07-13SaleChief Scientific Officer
1,916
0.0075%
$30.00$57,480+48.06%
2022-05-11SaleChief Scientific Officer
944
0.004%
$42.49$40,111+3.60%
2022-04-11SaleChief Scientific Officer
559
0.0024%
$64.15$35,860-29.72%
2022-04-06SaleChief Operating Officer
1,728
0.007%
$65.00$112,320-33.79%
2022-04-04SaleChief Scientific Officer
7,950
0.0315%
$60.00$477,000-30.15%
2022-04-01SaleChief Operating Officer
366
0.0015%
$57.97$21,217-25.78%
2022-03-11SaleChief Scientific Officer
875
0.0038%
$54.54$47,723-11.26%
2022-02-11SaleChief Scientific Officer
2,650
0.0112%
$52.06$137,965-10.70%
2022-01-11SaleChief Scientific Officer
2,650
0.0109%
$53.75$142,447-16.23%
2022-01-05Saledirector
4,034
0.0174%
$58.25$234,991-18.81%
2022-01-05SaleChief Scientific Officer
2,650
0.0118%
$60.00$159,000-18.81%
2022-01-04Saledirector
20,062
0.082%
$57.55$1.15M-21.81%
2022-01-03Saledirector
23,555
0.0959%
$58.01$1.37M-22.56%
2021-12-15SaleChief Scientific Officer
735
0.003%
$50.00$36,750-11.75%

Insider Historical Profitability

87.24%
ORBIMED ADVISORS LLCdirector
119522
0.2951%
$54.0611+122.73%
GORDON CARL Ldirector
119522
0.2951%
$54.0611+122.73%
Kariv Tomer
2288151
5.6487%
$54.0620+51.74%
Nussbaum Ran
2288151
5.6487%
$54.0620+51.74%
Pontifax Management 4 G.P. (2015) Ltd.10 percent owner
2288151
5.6487%
$54.0620+51.74%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$332.23M13.915.02M+29.54%+$75.75M0.02
BlackRock$143.39M62.17M+6.34%+$8.55M<0.01
Alkeon Capital Management Llc$105.85M4.431.6M+6.67%+$6.62M0.58
State Street$103.46M4.331.56M+48.23%+$33.66M<0.01
The Vanguard Group$102.33M4.281.55M+7.93%+$7.52M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.